We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: April 18, 2001
Last Update Posted: January 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
New York MDRU
Information provided by:
National Institute on Drug Abuse (NIDA)
The purpose of this study is the safety and efficacy of Buprenorphine/Naloxone in the treatment of opioid dependence. A compassionate use study.

Condition Intervention Phase
Opioid Dependence Substance-Related Disorders Drug: Buprenorphine/naloxone Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Buprenorphine/Nx Treatment of Heroin Dependence-A Compassionate Use Study

Resource links provided by NLM:

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Craving
  • Retention
  • Opioid withdrawal
  • Subjective rating

Enrollment: 582
Study Start Date: August 1999
Study Completion Date: September 2001
Primary Completion Date: August 2001 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Buprenorphine/Naloxone Drug: Buprenorphine/naloxone

Detailed Description:
The objective of this study is to provide follow-up compassionate use treatment and evaluate long term safety and efficacy of a buprenorphine/naloxone combination tablet for opiate dependence treatment for subjects who have completed Cooperative Study 1008 A and B.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 59 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

- Completion of Cooperative Study 1008 A/B

Exclusion Criteria:

- Significant medical or psychiatric illness. Non-compliance with study procedures in the Cooperative Study 1008 A/B

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00015340

United States, California
University of California
Los Angeles, California, United States, 90095
United States, Florida
VA Medical Center
Tampa, Florida, United States, 33612
United States, Illinois
VA Medical Center
Hines, Illinois, United States, 60141
United States, New York
New York VAMC
New York, New York, United States, 10010
United States, Washington
VA PUget Sound Helath Care System
Seattle, Washington, United States, 98108
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
New York MDRU
Study Chair: Paul Casadonte, M.D. New York VAMC
  More Information

ClinicalTrials.gov Identifier: NCT00015340     History of Changes
Other Study ID Numbers: NIDA-5-0013-14
First Submitted: April 18, 2001
First Posted: April 18, 2001
Last Update Posted: January 12, 2017
Last Verified: August 2016

Keywords provided by National Institute on Drug Abuse (NIDA):
Opioid Dependence

Additional relevant MeSH terms:
Substance-Related Disorders
Heroin Dependence
Chemically-Induced Disorders
Mental Disorders
Opioid-Related Disorders
Buprenorphine, Naloxone Drug Combination
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists